(212) 832-6047


Mr. Renaud Caumartin

Senior Managing Director – Head of Investment Banking

Mr. Caumartin is a Board Member at RW Pressprich. He has over 20 years of experience in capital raising, structured finance and creating solutions for institutional investors. Mr. Caumartin leverages his experience to assist our clients in evaluating their strategic alternatives and can provide services in all phases of the M&A or capital raising process from financial analysis, structuring of transactions, and closing financial terms tailored to the client’s needs and capital market demands. For example, Mr. Caumartin successfully completed the sale of a minority stake in Le Pain Quotiden to Cobepa. Mr. Caumartin is the Head of the International Desk at RW Pressprich, where as an Institutional Salesperson he has developed an extensive network of institutional investors from banks and insurance companies to hedge funds, private equity and asset managers. Mr. Caumartin is a Board Member at Histide, a biotech intellectual property Platform Company based in Switzerland. Mr. Caumartin started his career at Dexia in Paris as a Fixed Income Portfolio Manager and part of a team managing a €40 billion portfolio.

Mr. Caumartin earned his Master’s degree of Management Sciences and obtained his MBA from University of Paris Nanterre - France.

(212) 832-6316


Daniel D'Agostino, Jr.

Managing Director – Head of Healthcare

Dan joined RW Pressprich & Co. in June 2017. He has 20+ years of investment banking experience and is Head of Healthcare at Pressprich, a full-service investment bank focused on growth companies in the Healthcare, Technology and Consumer sectors. Prior to RWP, Dan was Managing Partner and CEO of AmeriTech Advisors a full-service investment bank focused on growth companies in the Medtech and Tech sectors from 2009-2017. Prior to ATA, Dan was at ThinkEquity Partners as a Managing Director and head of the healthcare investment banking from 2007 to 2009. Dan also served as acting CFO and Chief Business Officer of Synergy Pharmaceuticals (Nasdaq: SGYP) a bio-pharmaceutical company focused on GI conditions from 2003 to 2007. Prior to Synergy he was co-head of investment banking at Punk, Ziegel & Company where he was a partner for six years. Dan was also a mergers and acquisitions banker at Deutsche Bank/ BT Alex.Brown, Wasserstein, Perella & Co. and Credit Suisse. Dan is board member and chairman of the audit committee for SentrX Animal Care. Dan has closed transactions with Cytovia Therapeutics, BabelBark Inc., FAT Brands, bioMerieux SA, Apotex, Inc, Accelerate Dx, ArQule, Synergy Pharmaceuticals, Progenics Pharmaceuticals, Assertio Therapeutics (Depomed), Cell Therapeutics, EntreMed, Vion, Axonyx, Generac, JF Lehman, Beacon Group and many other strategic and financial groups. His experience includes leading buyside and sellside M&A; advisory assignments, IPO's, public debt and equity financings, senior debt facilities and private placements.

Dan earned an MBA in Finance and Masters Degree in International Affairs from Columbia University and a Bachelor of Science in Accounting from Tulane University and Program in Biotechnology for executives, School of Engineering at UPenn. He has his Series 24, 28, 79, 7, 63.